Skip to main content
COMPLICATED CASE HISTORIES

Efficacy of High-Dose Aripiprazole for Treatment-Resistant Schizoaffective Disorder: A Case Report

Psychopharmacology Bulletin 43(4): 70-72, 2011/01/07; https://doi.org/10.64719/pb.4306

Abstract

Aripiprazole is an atypical neuroleptic with a unique mechanism of action. According to the package insert, the maximum recommended dose for aripiprazole is 30 mg/day. In clinical practice, off-label prescribing of medications, including the use of doses that exceed the manufacturer’s recommendations, is not uncommon. Most premarketing studies are designed principally to demonstrate safety, efficacy, and tolerability and often exclude many patients who are treated after a drug has been released. To report a case with treatment-resistant schizoaffective disorder in which a patient tolerated and responded to high-dose aripiprazole; an objective is to discuss the use of aripiprazole dosages at higher than those recommended in the product’s labelling. Psychopharmacology Bulletin. 2010;43(4):70–72.

Access This Article

Choose an access option below to view the full article.

Subscriber Access

If you or your institution has a subscription, log in to access this article.

Log In

Purchase Article

Buy single-article access with a one-time purchase.

$30.00
Add to Cart

How to Cite

Omer Saatcioglu, Sevda Gumus, Kirkor Kamberyan, Medaim Yanik. Efficacy of High-Dose Aripiprazole for Treatment-Resistant Schizoaffective Disorder: A Case Report. Psychopharmacology Bulletin. 2011/01/07; 43(4):70-72. https://doi.org/10.64719/pb.4306